Dr. Reddy's Laboratories Limited has informed the Exchange that Board of Directors at its meeting held on May 09, 2025, recommended Final Dividend of Rs. 8 per equity share.
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts less than Nifty 100 and 0.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dr. Reddy's reported strong FY25 results with consolidated revenue of Rs. 32,554 crore (up 17% YoY) and Q4 revenue of Rs. 8,506 crore (up 20% YoY), aided by the acquired NRT business from Haleon. Q4 EBITDA margin expanded to 29.1% from 26.4% a year ago, while Q4 PAT attributable to shareholders rose 22% YoY to Rs. 1,594 crore. FY25 PAT grew modestly at 2% YoY to Rs. 5,654 crore due to higher costs and impairments of Rs. 169 crore on product intangibles. The Board recommended a final dividend of Rs. 8 per share (face value Rs. 1) for FY25, with record date fixed at July 10, 2025. Statutory auditors issued an unqualified/unmodified opinion on the financial statements. G V Prasad was re-appointed as Co-Chairman & MD for 5 years effective January 2026.
Positive for shareholders — strong Q4 performance with 20% revenue growth, expanding EBITDA margins, and a confirmed dividend payout signal healthy cash generation. Continued investment in R&D and recent acquisitions (Haleon NRT, Nestle nutraceuticals JV) support future growth, though gross margin pressure and ongoing FCPA investigation in the US remain watchpoints.